Company intelligence / Profile preview

CytoCares

Shanghai Shi, Shanghai, Chinazoominfo.com ↗

Ownership: Private
Development stage: Phase 1

Overview

CytoCares is a Shanghai-based immuno-oncology biotech developing first-in-class multi-specific antibody therapeutics. Its lead asset, CC312, is a trispecific antibody currently in Phase 1 trials targeting relapsed/refractory CD19-positive B-cell malignancies. The company also recently received IND approval in China to begin clinical studies of CC312 for systemic lupus erythematosus. Proprietary platforms target T cells, NK cells, and tumor-associated macrophages to stimulate anti-tumor immunity or modulate immune responses[1][2][3][4].

Therapeutic areas: OncologyImmunology
Modalities: Multi-specific antibodies (including trispecific T-cell engagers)Antibody therapeutics targeting immune cells (T cells, NK cells, macrophages)
Industry: Biotech

Drug pipeline

1 asset

CC312

Beyond the preview

Go deeper on CytoCares.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CytoCares.

Explore the full profile